Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging
- PMID: 38220125
- DOI: 10.1016/j.critrevonc.2023.104235
Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging
Abstract
Cholangiocarcinoma (CCA) is a highly aggressive hepatobiliary malignancy, second only to hepatocellular carcinoma in prevalence. Despite surgical treatment being the recommended method to achieve a cure, it is not viable for patients with advanced CCA. Gene sequencing and artificial intelligence (AI) have recently opened up new possibilities in CCA diagnosis, treatment, and prognosis assessment. Basic research has furthered our understanding of the tumor-immunity microenvironment and revealed targeted molecular mechanisms, resulting in immunotherapy and targeted therapy being increasingly employed in the clinic. Yet, the application of these remedies in CCA is a challenging endeavor due to the varying pathological mechanisms of different CCA types and the lack of expressed immune proteins and molecular targets in some patients. AI in medical imaging has emerged as a powerful tool in this situation, as machine learning and deep learning are able to extract intricate data from CCA lesion images while assisting clinical decision making, and ultimately improving patient prognosis. This review summarized and discussed the current immunotherapy and targeted therapy related to CCA, and the research progress of AI in this field.
Keywords: Cholangiocarcinoma; Deep learning; Immunotherapy; Machine learning; Targeted therapy.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Cholangiocarcinoma Evaluation via Imaging and Artificial Intelligence.Oncology. 2021;99(2):72-83. doi: 10.1159/000507449. Epub 2020 Nov 4. Oncology. 2021. PMID: 33147583 Review.
-
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).Int J Oncol. 2023 Dec;63(6):137. doi: 10.3892/ijo.2023.5585. Epub 2023 Oct 27. Int J Oncol. 2023. PMID: 37888583 Free PMC article. Review.
-
Computer auxiliary diagnosis technique of detecting cholangiocarcinoma based on medical imaging: A review.Comput Methods Programs Biomed. 2021 Sep;208:106265. doi: 10.1016/j.cmpb.2021.106265. Epub 2021 Jul 14. Comput Methods Programs Biomed. 2021. PMID: 34311415 Review.
-
Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.Int J Biol Sci. 2022 Aug 21;18(14):5369-5390. doi: 10.7150/ijbs.73949. eCollection 2022. Int J Biol Sci. 2022. PMID: 36147461 Free PMC article. Review.
-
Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.Ann Hepatol. 2018 Oct 16;17(6):969-979. doi: 10.5604/01.3001.0012.7197. Ann Hepatol. 2018. PMID: 30600299
Cited by
-
Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy.Am J Pathol. 2025 Mar;195(3):397-408. doi: 10.1016/j.ajpath.2024.11.004. Epub 2024 Dec 19. Am J Pathol. 2025. PMID: 39730075 Review.
-
Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions.Clin Exp Med. 2024 Aug 14;24(1):193. doi: 10.1007/s10238-024-01460-7. Clin Exp Med. 2024. PMID: 39141161 Free PMC article. Review.
-
Research trends and hotspots evolution of artificial intelligence for cholangiocarcinoma over the past 10 years: a bibliometric analysis.Front Oncol. 2025 Feb 13;14:1454411. doi: 10.3389/fonc.2024.1454411. eCollection 2024. Front Oncol. 2025. PMID: 40017633 Free PMC article. Review.
-
LncRNA LUCAT1 as a prognostic biomarker in cholangiocarcinoma through targeting miR-141-3p: clinical and functional insights.Hereditas. 2025 Jul 26;162(1):143. doi: 10.1186/s41065-025-00512-6. Hereditas. 2025. PMID: 40713875 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical